• 141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

  • Sep 30 2024
  • Length: 59 mins
  • Podcast

141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

  • Summary

  • Ruxolitinib vs triamcinolone -

    Topical tofacitinib for LPP/FFA -

    Locus of control in AD -

    Low-dose naltrexone for LPP/FFA -

    Alternative/complementary treatments for HSV -

    Want to donate to the cause? Do so here!

    Donate to the podcast: uofuhealth.org/dermasphere

    Check out our video content on YouTube:

    www.youtube.com/@dermaspherepodcast

    and VuMedi!: www.vumedi.com/channel/dermasphere/

    The University of Utah's Dermatology

    ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -

    ⁠ Connect with us!

    - Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC

    - Instagram: dermaspherepodcast

    - Facebook: www.facebook.com/DermaspherePodcast/

    - Check out Luke and Michelle’s other podcast,

    SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our

    friends at:

    - ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)

    - ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn

    more dermatology!

    Show More Show Less

What listeners say about 141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.